[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.7314/APJCP.2014.15.6.2511

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Liu, Lian-Ke (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)
Wu, Heng-Fang (Institute of Cardiovascular Disease, The First Affiliated Hospital of Nanjing Medical University)
Guo, Zhi-Rui (Institute of Cardiovascular Disease, The First Affiliated Hospital of Nanjing Medical University)
Chen, Xiang-Jian (Institute of Cardiovascular Disease, The First Affiliated Hospital of Nanjing Medical University)
Yang, Di (Institute of Cardiovascular Disease, The First Affiliated Hospital of Nanjing Medical University)
Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)
Zhang, Ji-Nan (Institute of Cardiovascular Disease, The First Affiliated Hospital of Nanjing Medical University)

Publication Information

Asian Pacific Journal of Cancer Prevention / v.15, no.6, 2014 , pp. 2511-2515 More about this Journal

Abstract

Objective: Lung cancer is one of the malignant tumors with greatest morbidity and mortality around the world. The keys to targeted therapy are discovery of lung cancer biomarkers to facilitate improvement of survival and quality of life for the patients with lung cancer. Translationally controlled tumor protein (TCTP) is one of the most overexpressed proteins in human lung cancer cells by comparison to the normal cells, suggesting that it might be a good biomarker for lung cancer. Materials and Methods: In the present study, the targeted efficacy of dihydroartemisinin (DHA) on TCTP expression in the A549 lung cancer cell model was explored. Results and Conclusions: DHA could inhibit A549 lung cancer cell proliferation, and simultaneously up-regulate the expression of TCTP mRNA, but down-regulate its protein expression in A549 cells. In addition, it promoted TCTP protein secretion. Therefore, TCTP might be used as a potential biomarker and therapeutic target for non-small cell lung cancers.

Keywords

Translationally controlled tumor protein; NCSLC; dihydroartemisinin; biomarker; targeted therapy;

Citations & Related Records

Times Cited By KSCI : 7 (Citation Analysis)

Reference
Cited By KSCI

1	Susini L, Besse S, Duflaut D et al (2008). TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ, 15, 1211-20. DOI ScienceOn
2	Nam W, Tak J, Ryu JK et al (2007). Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck, 29, 335-40. DOI ScienceOn
3	Rasheed SA, Efferth T, Asangani IA, et al (2010). First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer, 127, 1475-85. DOI ScienceOn
4	Sun Q, Teong B, Chen IF, et al (2014). Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells. J Biomed Mater Res B Appl Biomater, 102, 455-62. DOI ScienceOn
5	Wang F, Hu C, Hua X, et al (2013). Translationally controlled tumor protein, a dual functional protein involved in the immune response of the silkworm, Bombyx mori. PLoS One, 8, e69284. DOI
6	Lo WY, Wang HJ, Chiu CW, et al (2012). miR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: from quantitative proteomics to post-transcriptional study. J Proteomics, 77, 154-66. DOI ScienceOn
7	Liloglou T, Bediaga NG, Brown BR, et al (2014). Epigenetic biomarkers in lung cancer. Cancer Lett, 342, 200-12. DOI ScienceOn
8	Liu J, Yang XL, Li A, et al (2014). Epidemiological patterns of cancer incidence in southern china: based on 6 populationbased cancer registries. Asian Pac J Cancer Prev, 15, 1471-5. DOI ScienceOn
9	Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods, 25, 402-8. DOI ScienceOn
10	Lucibello M, Gambacurta A, Zonfrillo M, et al (2011). TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res, 317, 2479-89. DOI ScienceOn
11	Makridakis M, Vlahou A (2010). Secretome proteomics for discovery of cancer biomarkers. J Proteomics, 73, 2291-305. DOI ScienceOn
12	Miao X, Chen YB, Xu SL, et al (2013). TCTP overexpression is associated with the development and progression of glioma. Tumour Biol, 34, 3357-61. DOI
13	Molina JR, Adjei AA, Jett JR (2006). Advances in chemotherapy of non-small cell lung cancer. Chest, 130, 1211-9. DOI ScienceOn
14	Mu D, Zhang W, Chu D, et al (2008). The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother Pharmacol, 61, 639-45. DOI
15	Nagano-Ito M., Ichikawa S. (2012). Biological effects of Mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis. Biochem Res Int, 204960.
16	Handrick R, Ontikatze T, Bauer KD, et al (2010). Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther, 9, 2497-510. DOI ScienceOn
17	Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. DOI ScienceOn
18	Fathallah RM, Dajani R (2013). Comparison of population based cancer incidence rates among Circassians, Chechans and Arabs in Jordan (1996-2005). Asian Pac J Cancer Prev, 14, 6035-40. DOI ScienceOn
19	Fujita T, Felix K, Pinkaew D, et al (2008). Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett, 582, 1055-60. DOI ScienceOn
20	Jemal A, Bray F, Center MM et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI
21	Jiao Y, Ge CM, Meng QH, et al (2007). Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin, 28, 1045-56. DOI ScienceOn
22	Kim JE, Koo KH, Kim YH, et al (2008). Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med, 40, 709-20. DOI ScienceOn
23	Keating GM (2012). Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs, 72, 937-61. DOI ScienceOn
24	Lammers T, Kiessling F, Hennink WE, et al (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release, 161, 175-87. DOI ScienceOn
25	Amson R, Pece S, Marine JC, et al (2013). TPT1/TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol, 23, 37-46. DOI ScienceOn
26	Lee JH, Rho SB, Park SY, et al (2008). Interaction between fortilin and transforming growth factor-beta stimulated clone-22 (TSC-22) prevents apoptosis via the destabilization of TSC-22. FEBS Lett, 582, 1210-8. DOI ScienceOn
27	Al-Hashimi MM, Wang XJ. (2014). Trend analysis of lung cancer incidence rates in Ninawa province, Iraq, from 2000 to 2010--decrease and recent stability. Asian Pac J Cancer Prev, 15, 385-90. DOI ScienceOn
28	Amson R, Pece S, Lespagnol A, et al (2011). Reciprocal repression between P53 and TCTP. Nat Med, 18, 91-9. DOI ScienceOn
29	Chen H, Sun B, Wang S, et al (2010). Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest andinactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol, 136, 897-903. DOI ScienceOn
30	Chen T, Li M, Zhang R, et al (2009). Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med, 13, 1358-70. DOI ScienceOn
31	Choi S, Min HJ, Kim M, et al (2009). Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion. PLOS One, 4, 478-96.
32	Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. DOI ScienceOn
33	Deng W, Long L, Li JL, et al (2014). Mortality of major cancers in guangxi, china: sex, age and geographical differences from 1971 and 2005. Asian Pac J Cancer Prev, 15, 1567-74. DOI ScienceOn
34	Baylot V, Katsogiannou M, Andrieu C, et al (2012). Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther, 20, 2244-56. DOI
35	Dong X, Yang B, Li Y, et al (2009). Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J Biol Chem, 284, 23754-64. DOI ScienceOn
36	Acunzo J, Baylot V, So A2, et al (2014). TCTP as therapeutic target in cancers. Cancer Treat Rev, [Epub ahead of print].

5	Hua Jin. (2015) Molecular Medicine Reports RNA interference-mediated knockdown of translationally controlled tumor protein induces apoptosis, and inhibits growth and invasion in glioma cells / 12 (5) , 6617
1	Jian-Hui Shen. (2015) Biotechnology and Applied Biochemistry / 63 (1) , 5
5	Lin Zhou. (2016) Journal of Bone and Mineral Research Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways / 31 (5) , 964
13	(2016) Hepatology Research Serum translationally controlled tumor protein is involved in rat liver regeneration after hepatectomy / 46 (13) , 1392
1	(2017) Cell Communication and Signaling Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin / 15 (1)